Clinical Trial Update: Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating thalidomide for recurrent or persistent cancer of the uterus has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Corpus Leiomyosarcoma
• Uterine Corpus Sarcoma

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma | Phase 2 | Status: COMPLETED